Vertero Therapeutics

Vertero Therapeutics is a clinical-stage biopharmaceutical company headquartered in Woburn, Massachusetts, in the United States. The company describes its mission as changing the perception and treatment of neurodegenerative diseases in order to delay disease progression and preserve patients' quality of life for as long as possible. Rather than focusing solely on the brain, Vertero's scientific approach is built around the idea that important drivers of neurodegenerative disease lie outside the central nervous system, in the peripheral nervous system and particularly in the gut. Vertero's stated innovation is to pioneer science "beyond the brain" to address upstream drivers of challenging neurodegenerative diseases. The company says it combines an unorthodox mindset with data-driven innovation to design oral therapeutics that precisely modulate peripheral targets known to accelerate brain disease, aiming to disrupt the course of disease at its source. Its multidisciplinary team includes specialists in microbiology, pharmacology, chemistry, neurology, and clinical development. The company's lead candidate is VT-5006, an oral therapeutic designed to precisely treat a validated target in the gut that feeds the protein aggregation and inflammation that drives Parkinson's disease. Vertero has advanced VT-5006 into clinical study; its website reports that the first patient with Parkinson's disease was dosed in a Phase 1b clinical study of VT-5006, and a news item dated May 19, 2026, describes Vertero advancing into a Phase 1b study with VT-5006 for the treatment of Parkinson's disease. Vertero is led by Chief Executive Officer A. Stewart Campbell, PhD, who joined the company in 2017 and was appointed CEO in February 2021. According to the company, he has played a fundamental role in its growth and strategy and has secured multiple rounds of equity financing to support its advancement. The company presents itself as a private, venture-backed biopharmaceutical developer rather than a commercial-stage pharmaceutical manufacturer, and its public communications emphasize pipeline progress, clinical milestones, and scientific differentiation.

Vertero Therapeutics is a United States-based biopharmaceutical company located in Woburn, Massachusetts. Public information about the company is concentrated in its own corporate communications and a Wikidata entry identifying it as a company in Woburn, United States. The company's own account of its development centers on its scientific program and its leadership rather than on a long corporate history. A. Stewart Campbell, PhD, joined Vertero Therapeutics in 2017 and was appointed the company's Chief Executive Officer in February 2021. According to the company, Campbell has played a fundamental role in its growth and strategy, bringing more than 30 years of experience leading and building teams with strong track records of discovering and developing novel therapeutics. As CEO, he secured multiple rounds of equity financing to support the advancement and growth of Vertero. Before joining Vertero, Campbell held various leadership roles at biopharmaceutical and chemical manufacturing companies, including Corden Pharma, Ancora Pharmaceuticals (where he led its acquisition by Corden), Surface Logix, and Insmed, after starting his career as a medicinal chemist at Boehringer-Ingelheim. During his career he has been a co-inventor on more than 20 issued patent families. Vertero's scientific premise is that many standard-of-care therapies for neurodegenerative disease address symptoms, while the causative mechanisms may lie outside the brain, in the peripheral nervous system. The company states that its discoveries target these causative mechanisms and that its multidisciplinary team of specialists in microbiology, pharmacology, chemistry, neurology, and clinical development has enabled a novel approach to treating neurodegenerative diseases. Its stated mission is to change the perception and treatment of neurodegenerative diseases to delay disease progression and preserve quality of life for patients as long as possible. The company's lead candidate, VT-5006, is described as an oral therapeutic designed to precisely treat a validated target in the gut that feeds the protein aggregation and inflammation that drives Parkinson's disease. Vertero reports that the first patient with Parkinson's disease was dosed in a Phase 1b clinical study of VT-5006, and a news item dated May 19, 2026, states that Vertero advanced into a Phase 1b study with VT-5006 for the treatment of Parkinson's disease. A further news item is dated December 16, 2025. These clinical-stage activities position Vertero as a development-stage company rather than a commercial-stage manufacturer, and its public materials emphasize pipeline progress and scientific differentiation.

• 2026

  First patient with Parkinson's disease dosed in Phase 1b clinical study of VT-5006; news item dated May 19, 2026, announces advancement into Phase 1b study.

• 2025

  Vertero news item dated December 16, 2025.

• 2021

  A. Stewart Campbell is appointed Chief Executive Officer in February 2021.

• 2017

  A. Stewart Campbell, PhD, joins Vertero Therapeutics.

Clinical-stage biopharmaceutical company developing oral, peripherally acting therapeutics that target gut-based mechanisms driving neurodegenerative disease, with an initial focus on Parkinson's disease.

• VT-5006

  Lead oral therapeutic candidate designed to precisely treat a validated target in the gut that feeds the protein aggregation and inflammation that drives Parkinson's disease; advanced into a Phase 1b clinical study.

1. 1Vertero | Homevertero.com
2. 2Vertero | Aboutvertero.com
3. 3Vertero Therapeutics (United States) - Wikidatawikidata.org